mln2480
Small moleculeexperimental
Clinical trial activity
6 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Sep 15, 2011 (NCT01425008)
Timeline
Indications
Approved for
Studied for
- Astrocytoma · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Craniopharyngioma · Phase 2
- Glioma · Phase 3
- Melanoma · Phase 1/Phase 2
- Mutation · Phase 1/Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Proto-Oncogene Proteins B-raf · Phase 1/Phase 2
- Thyroid Cancer, Papillary · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- RAF serine/threonine protein kinaseINHIBITOR
RAF serine/threonine protein kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1- Mol. weight
- 506.3 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3348923 ↗
Also known as
- mln2480
- mln2480
- mln-2480
- mln-2480
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05566795 | Phase 3 | Oct 31, 2022 | Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium |
| NCT05465174 | Phase 2 | Sep 12, 2022 | Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc., University of California, San Francisco, University of Pennsylvania |
| NCT04985604 | Phase 1/Phase 2 (Phase 2) | Jul 15, 2021 | Day One Biopharmaceuticals, Inc. |
| NCT04775485 | Phase 2 | Mar 17, 2021 | Day One Biopharmaceuticals, Inc., The Pacific Pediatric Neuro-Oncology Consortium |
| NCT02327169 | Phase 1 | Feb 2, 2015 | Millennium Pharmaceuticals, Takeda |
| NCT01425008 | Phase 1 | Sep 15, 2011 | Millennium Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. | For profit | 4 | 3 | 2 | 2021 |
| Millennium Pharmaceuticals | For profit | 2 | 2 | 1 | 2011 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2022 |
| SIOPe Brain Tumor Group LOGGIC Consortium | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Takeda | For profit | 1 | 0 | 1 | 2015 |
| The Pacific Pediatric Neuro-Oncology Consortium | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1